07.01.2013 Views

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

IDSBS<br />

60617<br />

organomegaly, intellectual disabilities, short stature, and skeletal abnormalities. Mucopolysaccharidosis I<br />

(MPS I) is an autosomal recessive disorder caused by a reduced or absent activity of the enzyme<br />

alpha-L-iduronidase due to mutations in the IDUA gene. More than 100 mutations have been reported in<br />

individuals with MPS I. Deficiency of alpha-L-iduronidase can result in a wide range of phenotypes<br />

categorized into 3 syndromes: Hurler syndrome (MPS IH), Scheie syndrome (MPS IS), and Hurler-Scheie<br />

syndrome (MPS IH/S). Because these syndromes cannot be distinguished biochemically, they are also<br />

referred to as MPS I and attenuated MPS I. Clinical features and severity of symptoms of MPS I are<br />

variable, ranging from severe disease to an attenuated form that generally presents at a later onset with a<br />

milder clinical presentation. In general, symptoms may include coarse facies, progressive dysostosis<br />

multiplex, hepatosplenomegaly, corneal clouding, hearing loss, intellectual disabilities or learning<br />

difficulties, and cardiac valvular disease. The incidence of MPS I is approximately 1 in 100,000 live<br />

births. Treatment options include hematopoietic stem cell transplantation and enzyme replacement<br />

therapy. A diagnostic workup in an individual with MPS I typically demonstrates elevated levels of<br />

urinary GAG (MPSQN/81473 Mucopolysaccharides [MPS], Quantitative, Urine) and increased amounts<br />

of both dermatan and heparan sulfate detected on thin-layer chromatography (MPSSC/84464<br />

Mucopolysaccharides [MPS] Screen, Urine). Reduced or absent activity of alpha L-iduronidase in blood<br />

spots (IDSBS/60617 Alpha-L-Iduronidase, Blood Spot), fibroblasts (IDST/8780 Alpha-L-Iduronidase,<br />

Fibroblasts), leukocytes, or whole blood can confirm a diagnosis of MPS I; however, enzymatic testing is<br />

not reliable for carrier detection. Molecular sequence analysis of the IDUA gene allows for detection of<br />

the disease-causing mutation in affected patients and subsequent carrier detection in relatives. To date, a<br />

clear genotype-phenotype correlation has not been established.<br />

Useful For: Diagnosis of mucopolysaccharidosis I, Hurler, Scheie, and Hurler-Scheie syndromes in<br />

whole blood<br />

Interpretation: Specimens with results or =1.0<br />

nmol/h/mL) are not consistent with alpha-L-iduronidase deficiency.<br />

Reference Values:<br />

> or = 1.0 nmol/h/mL<br />

An interpretive report will be provided.<br />

Clinical References: 1. Neufeld EF, Muenzer J: The mucopolysaccharidoses. In The Metabolic and<br />

Molecular Basis of Inherited Disease. Vol 3. 8th edition. Edited by CR Scriver, AL Beaudet, WS Sly, et<br />

al. McGraw-Hill, <strong>Medical</strong> Publishing Division, 2001, pp 3421 2. Chamoles NA, Blanco M, Gaggioli D,<br />

Casentini C: Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem<br />

2001;47:2098-2102 3. Martins AM, Dualibi AP, Norato D, et al: Guidelines for the management of<br />

mucopolysaccharidosis type I. J Pediatr 2009 Oct;155(4 Suppl):S32-46 4. Enns GM, Steiner RD, Cowan<br />

TM: Lysosomal disorders: mucopolysaccharidoses. In Pediatric Endocrinology and Inborn Errors of<br />

Metabolism. Edited by K Sarafoglou, GF Hoffmann, KS Roth. McGraw-Hill, <strong>Medical</strong> Publishing<br />

Division, 2009, pp 721-730 5. Clarke LA, Heppner J: Mucopolysaccharidosis Type I. GeneReviews.<br />

Edited by RA Pagon, TD Bird, CR Dolan, et al. University of Washington, Seattle. Last updated July<br />

2011<br />

Alpha-L-Iduronidase, Blood Spot<br />

Clinical Information: The mucopolysaccharidoses are a group of lysosomal storage disorders caused<br />

by the deficiency of any of the enzymes involved in the stepwise degradation of dermatan sulfate, heparan<br />

sulfate, keratan sulfate, or chondroitin sulfate (glycosaminoglycans; GAG). Accumulation of GAG<br />

(previously called mucopolysaccharides; MPS) in lysosomes interferes with normal functioning of cells,<br />

tissues, and organs. There are 11 known disorders that involve the accumulation of GAG. MPS disorders<br />

involve multiple organ systems characterized by coarse facial features, cardiac abnormalities,<br />

organomegaly, intellectual disabilities, short stature and skeletal abnormalities. Mucopolysaccharidosis I<br />

(MPS I) is an autosomal recessive disorder caused by a reduced or absent activity of the enzyme<br />

alpha-L-iduronidase due to mutations in the IDUA gene. More than 100 mutations have been reported in<br />

individuals with MPS I. Deficiency of alpha-L-iduronidase can result in a wide range of phenotypes<br />

Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or <strong>Mayo</strong><strong>Medical</strong><strong>Laboratories</strong>.com Page 95

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!